LIMTLocal Insertion Media Technology
References in periodicals archive ?
LIMT HDV, an international study with sites in New Zealand, Israel and Pakistan, is a 1: 1 randomized, open-label study of Lambda 120 or 180 microgram subcutaneous injections administered weekly for 48 weeks in 33 patients with chronic HDV.
Eiger BioPharmaceuticals, a clinical-stage biopharmaceutical company, has dosed the first patient in the Phase 2 LIMT HDV (Lambda Interferon MonoTherapy in HDV) study, a monotherapy trial of pegylated interferon lambda 1a (Lambda), it was reported yesterday.
Eiger senior vice president of liver and infectious diseases drug development, Eduardo Martins, said, 'We are excited to begin dosing HDV-infected patients with Lambda in the LIMT HDV study.